Paullones as inhibitors of protein kinases

Current Topics in Medicinal Chemistry

Volumn 11, Issue 11, 2011, Pages 1320-1332

  Tolle, Nadine ^a   Kunick, Conrad ^a  

^a TECHNICAL UNIVERSITY OF BRAUNSCHWEIG   (Germany)

Author keywords

Azepinones; Cyclin dependent kinases; GSK 3; Indoles; Paullones

Indexed keywords

ALSTERPAULLONE; AMYLOID PRECURSOR PROTEIN; CYCLIN DEPENDENT KINASE; GLYCOGEN SYNTHASE KINASE 3; KENPAULLONE; METAL COMPLEX; PAULLONE; PAULLONE DERIVATIVE; PROTEIN KINASE; TAU PROTEIN; WNT PROTEIN;

ALZHEIMER DISEASE; ANTIMICROBIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BIOLOGICAL ACTIVITY; BRAIN CELL; CHEMICAL STRUCTURE; CYTOTOXICITY; DRUG TARGETING; EMBRYO DEVELOPMENT; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; LEISHMANIA DONOVANI; LEISHMANIA MEXICANA; NERVE CELL; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PLURIPOTENT STEM CELL; PROTEIN PHOSPHORYLATION; REVIEW; STEM CELL; TRYPANOSOMA BRUCEI;

ANIMALS; BENZAZEPINES; DRUG DISCOVERY; HUMANS; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 79958092650     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/156802611795589601     Document Type: Review

References (105)

1. Kunick, C. Synthese von 7,12-Dihydro-indolo[3,2-d][1] benzazepin-6(5H)-onen und 6,11-Dihydro-thieno[3',2':2,3]azepino[4,5-b]indol-5(4H)-on. Arch. Pharm. (Weinheim), 1992, 325, 297-299.
2. Boyd, M. R. Status of the NCI preclinical antitumor drug discovery screen. Principles Practice Oncol., 1989, 3, 1-12.
3. Boyd, M. R.; Paull, K. D. Some practical considerations and applications of the National Cancer Institute anticancer drug discovery screen. Drug Dev. Res., 1995, 34, 91-109.
4. Monks, A.; Scudiero, D. A.; Johnson, G. S.; Paull, K. D.; Sausville, E. A. The NCI anti-cancer drug screen: a smart screen to identify effectors of novel targets. Anti-Cancer Drug Des., 1997, 12, 533-541.
5. Paull, K. D.; Shoemaker, R. H.; Hodes, L.; Monks, A.; Scudiero, D. A.; Rubinstein, L.; Plowman, J.; Boyd, M. R. Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of meangraph and COMPARE algorithm. J. Natl. Cancer Inst., 1989, 81, 1088-1092.
6. Shoemaker, R. H. The NCI60 human tumour cell line anticancer drug screen. Nat. Rev. Cancer, 2006, 6, 813-823.
7. Weinstein, J. N.; Myers, T. G.; O'Connor, P. M.; Friend, S. H.; Fornace Jr., A. J.; Kohn, K. W.; Fojo, T.; Bates, S. E.; Rubinstein, L. V.; Anderson, N. L.; Buolamwini, J. K.; van Osdol, W. W.; Monks, A. P.; Scudiero, D. A.; Sausville, E. A.; Zaharevitz, D. W.; Bunow, B.; Viswanadhan, V. N.; Johnson, G. S.; Wittes, R. E.; Paull, K. D. An information-intensive approach to the molecular pharmacology of cancer. Science, 1997, 275, 343-349.
8. Kunick, C.; Bleeker, C.; Prühs, C.; Totzke, F.; Schächtele, C.; Kubbutat, M. H. G.; Link, A. Matrix compare analysis discriminates subtle structural differences in a family of novel antiproliferative agents, diaryl-3-hydroxy-2,3,3a,10atetrahydrobenzo[b]cyclopenta[e]azepine-4,10(1H,5H)-diones. Bioorg. Med. Chem. Lett., 2006, 16, 2148-2153.
9. Kelland, L. R. Flavopiridol, the first cyclin-dependent kinase inhibitor to enter the clinic: current status. Expert Opin. Investig. Drugs, 2000, 9, 2903-2911.
10. Sedlacek, H. H.; Czech, J.; Naik, R.; Kaur, G.; Worland, P.; Losiewicz, M.; Parker, B.; Carlson, B.; Smith, A.; Senderowicz, A.; Sausville, E. Flavopiridol (L86-8275, NSC-649890), a new kinase inhibitor for tumor therapy. Int. J. Oncol., 1996, 9, 1143-1168.
11. Zhai, S.; Senderowicz, A. M.; Sausville, E. A.; Figg, W. D. Flavopiridol, a novel cyclin-dependent kinase inhibitor, in clinical development. Ann. Pharmacother., 2002, 36, 905-911.
12. Sausville, E. A.; Zaharevitz, D.; Gussio, R.; Meijer, L.; Louarn-Leost, M.; Kunick, C.; Schultz, R.; Lahusen, T.; Headlee, D.; Stinson, S.; Arbuck, S. G.; Senderowicz, A. Cyclin-dependent kinases: Initial approaches to exploit a novel therapeutic target. Pharmacol. Ther., 1999, 82, 285-292.
13. Zaharevitz, D. W.; Gussio, R.; Leost, M.; Senderowicz, A.; Lahusen, T.; Kunick, C.; Meijer, L.; Sausville, E. A. Discovery and initial characterization of the paullones, a novel class of smallmolecule inhibitors of cyclin-dependent kinases. Cancer Res., 1999, 59, 2566-2569.
14. Gussio, R.; Zaharevitz, D. W.; McGrath, C. F.; Pattabiraman, N.; Kellogg, G. E.; Schultz, C.; Link, A.; Kunick, C.; Leost, M.; Meijer, L.; Sausville, E. A. Structure-based design modifications of the paullone molecular scaffold for cyclin-dependent kinase inhibition. Anti-Cancer Drug Des., 2000, 15, 53-66.
15. McGrath, C. F.; Pattabiraman, N.; Kellogg, G. E.; Lemcke, T.; Kunick, C.; Sausville, E. A.; Zaharevitz, D. W.; Gussio, R. Homology Model of the CDK1/cyclin B Complex. J. Biomol. Struct. Dyn., 2005, 493-502.
16. Schultz, C.; Link, A.; Leost, M.; Zaharevitz, D. W.; Gussio, R.; Sausville, E. A.; Meijer, L.; Kunick, C. Paullones, a series of cyclin-dependent kinase inhibitors: synthesis, evaluation of CDK1/ cyclin B inhibition, and antitumor activity. J. Med. Chem., 1999, 42, 2909-2919.
17. Kozikowski, A. P.; Ma, D.; Brewer, J.; Sun, S.; Costa, E.; Romeo, E.; Guidotti, A. Chemistry, binding affinities, and behavioral properties of a new class of "antineophobic" mitochondrial DBI receptor complex (mDRC) ligands. J. Med. Chem., 1993, 36, 2908-2920.
18. Rayasam, G. V.; Tulasi, V. K.; Sodhi, R.; Davis, J. A.; Ray, A. Glycogen synthase kinase 3: more than a namesake. Br. J. Pharmacol., 2009, 156, 885-898.
19. Cohen, P.; Goedert, M. GSK3 inhibitors: development and therapeutic potential. Nat. Rev. Drug Discov., 2004, 3, 479-487.
20. Martinez, A.; Castro, A.; Dorronsoro, I.; Alonso, M. Glycogen synthase kinase 3 (GSK-3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation. Med. Res. Rev., 2002, 22, 373-384.
21. Meijer, L.; Flajolet, M.; Greengard, P. Pharmacological inhibitors of glycogen synthase kinase-3. Trends Pharmacol. Sci., 2004, 25, 471-480.
22. Leost, M.; Schultz, C.; Link, A.; Wu, Y.-Z.; Biernat, J.; Mandelkow, E.-M.; Bibb, J. A.; Snyder, G. L.; Greengard, P.; Zaharevitz, D. W.; Gussio, R.; Senderowicz, A. M.; Sausville, E. A.; Kunick, C.; Meijer, L. Paullones are potent inhibitors of glycogen synthase kinase-3beta and cyclin-dependent kinase 5/p25. Eur. J. Biochem., 2000, 267, 5983-5994.
23. Bertrand, J. A.; Thieffine, S.; Vulpetti, A.; Cristiani, C.; Valsasina, B.; Knapp, S.; Kalisz, H. M.; Flocco, M. Structural characterization of the GSK-3beta active site using selective and non-selective ATP-mimetic inhibitors. J. Mol. Biol., 2003, 333, 393-407.
24. Kunick, C.; Schultz, C.; Lemcke, T.; Zaharevitz, D. W.; Gussio, R.; Jalluri, R. K.; Sausville, E. A.; Leost, M.; Meijer, L. 2-Substituted paullones: CDK1/cyclin B-inhibiting property and antiproliferative activity. Bioorg. Med. Chem. Lett., 2000, 10, 567-569.
25. Xie, X.; Lemcke, T.; Gussio, R.; Zaharevitz, D. W.; Leost, M.; Meijer, L.; Kunick, C. Epoxide-containing side chains enhance antiproliferative activity of paullones. Eur. J. Med. Chem., 2005, 40, 655-661.
26. Kunick, C.; Zeng, Z.; Gussio, R.; Zaharevitz, D.; Leost, M.; Totzke, F.; Schächtele, C.; Kubbutat, M. H. G.; Meijer, L.; Lemcke, T. Structure-aided optimization of kinase inhibitors derived from alsterpaullone. ChemBioChem, 2005, 6, 541-549.
27. Wieking, K.; Knockaert, M.; Leost, M.; Zaharevitz, D. W.; Meijer, L.; Kunick, C. Synthesis of paullones with aminoalkyl side chains. Arch. Pharm. Pharm. Med. Chem., 2002, 335, 311-317.
28. Bain, J.; McLauchlan, H.; Elliott, M.; Cohen, P. The specifities of protein kinase inhibitors: an update. Biochem. J., 2003, 371, 199-204.
29. Bain, J.; Plater, L.; Elliott, M.; Shpiro, N.; Hastie, C. J.; McLauchlan, H.; Klevernic, I.; Arthur, J. S.; Alessi, D. R.; Cohen, P. The selectivity of protein kinase inhibitors: a further update. Biochem. J., 2007, 408, 297-315.
30. Kunick, C.; Lauenroth, K.; Leost, M.; Meijer, L.; Lemcke, T. 1-Azakenpaullone is a selective inhibitor of glycogen synthase kinase-3. Bioorg. Med. Chem. Lett., 2004, 14, 413-416.
31. Stukenbrock, H.; Mussmann, R.; Geese, M.; Ferandin, Y.; Lozach, O.; Lemcke, T.; Kegel, S.; Lomow, A.; Burk, U.; Dohrmann, C.; Meijer, L.; Austen, M.; Kunick, C. 9-Cyano-1-azapaullone (cazpaullone), a glycogen synthase kinase-3 (GSK-3) inhibitor activating pancreatic beta cell protection and replication. J. Med. Chem., 2008, 51, 2196-2207.
32. Pies, T.; Schaper, K.-J.; Leost, M.; Zaharevitz, D. W.; Gussio, R.; Meijer, L.; Kunick, C. CDK1-inhibitory activity of paullones depends on electronic properties of 9-substituents. Arch. Pharm. Pharm. Med. Chem., 2004, 337, 486-492.
33. Kunick, C.; Lauenroth, K.; Wieking, K.; Xie, X.; Schultz, C.; Gussio, R.; Zaharevitz, D.; Leost, M.; Meijer, L.; Weber, A.; Jorgensen, F. S.; Lemcke, T. Evaluation and comparison of 3D-QSAR CoMSIA models for CDK1, CDK5, and GSK-3 inhibition by paullones. J. Med. Chem., 2004, 47, 22-36.
34. Kunick, C. Synthese [b]-kondensierter Azepindione durch Dealkoxycarbonylierung. Arch. Pharm., (Weinheim) 1991, 324, 579-581.
35. Baudoin, O.; Cesario, M.; Guénard, D.; Guéritte, F. Application of the palladium-catalyzed borylation/Suzuki coupling (BSC) reaction to the synthesis of biologically active biaryl lactams. J. Org. Chem., 2002, 67, 1199-1207.
36. Henry, N.; Blu, J.; Beneteau, V.; Merour, J.-Y. New route to the 5,12-dihydro-7H-benzo[2,3]azepino[4,5-b]indol-6-one core via a tin-mediated indole synthesis. Synthesis, 2006, 3895-3901.
37. Opatz, T.; Ferenc, D. Synthesis of the CDK-inhibitor paullone by cyclization of a deprotonated alpha-aminonitrile. Synthesis, 2008, 3941-3944.
38. Avila-Zarraga, J. G.; Lujan-Montelongo, A.; Covarrubias-Zuniga, A.; Romero-Ortega, M. New Heck coupling strategies for the synthesis of paullone and dimethyl paullone. Tetrahedron Lett., 2006, 47, 7987-7989.
39. Joucla, L.; Popowycz, F.; Lozach, O.; Meijer, L.; Joseph, B. Access to paullone analogues by intramolecular Heck reaction. Helv. Chim. Acta, 2007, 90, 753-763.
40. Joucla, L.; Putey, A.; Joseph, B. Synthesis of fused heterocycles with a benzazepinone moiety via intramolecular Heck coupling. Tetrahedron Lett., 2005, 46, 8177-8179.
41. Beccalli, E. M.; Broggini, G.; Martinelli, M.; Paladino, G.; Rossi, E. Practical and efficient palladium-promoted synthesis of indole systems containing medium-and large-ring-fused heterocycles. Synthesis, 2006, 2404-2412.
42. Bremner, J. B.; Sengpracha, W. An iodoacetamide-based free radical cyclization approach to the 7,12-dihydroindolo[3,2-d][1]benzazepin-6(5H)-one (paullone) system. Tetrahedron, 2005, 61, 5489-5498.
43. Becker, A.; Kohfeld, S.; Pies, T.; Wieking, K.; Preu, L.; Kunick, C. Synthesis of 11H-indolo[3,2-c]quinoline-6-carboxylic acids by cascade autoxidation-ring contractions. Synthesis, 2009, 1185-1189.
44. Greenwald, R. B.; Zhao, H.; Xia, J.; Wu, D.; Nervi, S.; Stinson, S. F.; Majerova, E.; Bramhall, C.; Zaharevitz, D. W. Poly(ethylene glycol) prodrugs of the CDK inhibitor, alsterpaullone (NSC 705701): synthesis and pharmacokinetic studies. Bioconjug. Chem., 2004, 15, 1076-1083.
45. Soni, D. V.; Jacobberger, J. W. Inhibition of cdk1 by alsterpaullone and thioflavopiridol correlates with increased transit time from mid G(2) through prophase. Cell Cycle, 2004, 3, 349-357.
46. Zhang, F.; Rabinovici, R. Adenosine deaminase acting on RNA 1 accelerates cell cycle through increased translation and activity of cyclin-dependent kinase 2. Shock, 2007, 27, 214-219.
47. Lin, W.; Wu, J.; Dong, H.; Bouck, D.; Zeng, F. Y.; Chen, T. Cyclin-dependent kinase 2 negatively regulates human pregnane X receptor-mediated CYP3A4 gene expression in HepG2 liver carcinoma cells. J. Biol. Chem., 2008, 283, 30650-30657.
48. Fromaget, M.; Cook, P. R. Photobleaching reveals complex effects of inhibitors on transcribing RNA polymerase II in living cells. Exp. Cell. Res., 2007, 313, 3026-3033.
49. Cole, A.; Frame, S.; Cohen, P. Further evidence that the tyrosine phosphorylation of glycogen synthase kinase-3 (GSK3) in mammalian cells is an autophosphorylation event. Biochem. J., 2004, 377, 249-255.
50. Tighe, A.; Ray-Sinha, A.; Staples, O. D.; Taylor, S. S. GSK-3 inhibitors induce chromosome instability. BMC Cell Biol., 2007, 8,34.
51. Kaladchibachi, S. A.; Doble, B.; Anthopoulos, N.; Woodgett, J. R.; Manoukian, A. S. Glycogen synthase kinase 3, circadian rhythms, and bipolar disorder: a molecular link in the therapeutic action of lithium. J. Circadian Rhythms, 2007, 5,3.
52. Finlay, D.; Patel, S.; Dickson, L. M.; Shpiro, N.; Marquez, R.; Rhodes, C. J.; Sutherland, C. Glycogen synthase kinase-3 regulates IGFBP-1 gene transcription through the thymine-rich insulin response element. BMC Mol. Biol., 2004, 5,15.
53. Mussmann, R.; Geese, M.; Harder, F.; Kegel, S.; Andag, U.; Lomow, A.; Burk, U.; Onichtchouk, D.; Dohrmann, C.; Austen, M. Inhibition of GSK3 promotes replication and survival of pancreatic beta cells. J. Biol. Chem., 2007, 282, 12030-12037.
54. Chao, J. I.; Kuo, P. C.; Hsu, T. S. Down-regulation of survivin in nitric oxide-induced cell growth inhibition and apoptosis of the human lung carcinoma cells. J. Biol. Chem., 2004, 279, 20267-20276.
55. Lahusen, T.; De Siervi, A.; Kunick, C.; Senderowicz, A. M. Alsterpaullone, a novel cyclin-dependent kinase inhibitor, induces apoptosis by activation of caspase 9 due to perturbation in mitochondrial membrane potential. Mol. Carcinog., 2003, 36, 183-194.
56. Dash, P. R.; Whitley, G. S.; Ayling, L. J.; Johnstone, A. P.; Cartwright, J. E. Trophoblast apoptosis is inhibited by hepatocyte growth factor through the Akt and beta-catenin mediated upregulation of inducible nitric oxide synthase. Cell. Signal., 2005, 17, 571-580.
57. Li, Z.; Tan, F.; Thiele, C. J. Inactivation of glycogen synthase kinase-3beta contributes to brain-derived neutrophic factor/TrkBinduced resistance to chemotherapy in neuroblastoma cells. Mol. Cancer Ther., 2007, 6, 3113-3121.
58. Yeh, P. A.; Chien, J. Y.; Chou, C. C.; Huang, Y. F.; Tang, C. Y.; Wang, H. Y.; Su, M. T. Drosophila notal bristle as a novel assessment tool for pathogenic study of tau toxicity and screening of therapeutic compounds. Biochem. Biophys. Res. Commun., 2010, 391, 510-516.
59. Tatebayashi, Y.; Haque, N.; Tung, Y. C.; Iqbal, K.; Grundke-Iqbal, I. Role of tau phosphorylation by glycogen synthase kinase-3{beta} in the regulation of organelle transport. J. Cell Sci., 2004, 1653-1663.
60. Selenica, M. L.; Jensen, H. S.; Larsen, A. K.; Pedersen, M. L.; Helboe, L.; Leist, M.; Lotharius, J. Efficacy of small-molecule glycogen synthase kinase-3 inhibitors in the postnatal rat model of tau hyperphosphorylation. Br. J. Pharmacol., 2007, 152, 959-979.
61. Phiel, C. J.; Wilson, C. A.; Lee, V. M.-Y.; Klein, P. S. GSK-3 regulates production of Alzheimer's disease amyloid-beta peptides. Nature, 2003, 423, 435-439.
62. Yuskaitis, C. J.; Jope, R. S. Glycogen synthase kinase-3 regulates microglial migration, inflammation, and inflammation-induced neurotoxicity. Cell. Signal., 2009, 21, 264-273.
63. Jordà, E. G.; Verdaguer, E.; Jimenez, A.; Arriba, S. G.; Allgaier, C.; Pallàs, M.; Camins, A. Evaluation of the neuronal apoptotic pathways involved in cytoskeletal disruption-induced apoptosis. Biochem. Pharmacol., 2005, 70, 470-480.
64. Takadera, T.; Fujibayashi, M.; Kaniyu, H.; Sakota, N.; Ohyashiki, T. Caspase-dependent apoptosis induced by thapsigargin was prevented by glycogen synthase kinase-3 inhibitors in cultured rat cortical neurons. Neurochem. Res., 2007, 32, 1336-1342.
65. Takadera, T.; Yoshikawa, R.; Ohyashiki, T. Thapsigargin-induced apoptosis was prevented by glycogen synthase kinase-3 inhibitors in PC12 cells. Neurosci. Lett., 2006, 408, 124-128.
66. Takadera, T.; Ohyashiki, T. Caspase-dependent apoptosis induced by calcineurin inhibitors was prevented by glycogen synthase kinase-3 inhibitors in cultured rat cortical cells. Brain Res., 2007, 1133, 20-26.
67. Takadera, T.; Ohyashiki, T. Calmodulin inhibitor-induced apoptosis was prevented by glycogen synthase kinase-3 inhibitors in PC12 cells. Cell. Mol. Neurobiol., 2007, 27, 783-790.
68. Takadera, T.; Sakamoto, Y.; Hizume, Y.; Ohyashiki, T. Cyclosporine A-and FK506-induced apoptosis in PC12 cells. Cell. Biol. Toxicol., 2007, 23, 355-360.
69. Petit-Paitel, A.; Brau, F.; Cazareth, J.; Chabry, J. Involvment of cytosolic and mitochondrial GSK-3beta in mitochondrial dysfunction and neuronal cell death of MPTP/MPP-treated neurons. PLoS One, 2009, 4, e5491.
70. Castelo-Branco, G.; Rawal, N.; Arenas, E. GSK-3beta inhibition/ beta-catenin stabilization in ventral midbrain precursors increases differentiation into dopamine neurons. J. Cell Sci., 2004, 117, 5731-5737.
71. Cadigan, K. M.; Nusse, R. Wnt signaling: a common theme in animal development. Genes Dev., 1997, 11, 3286-3305.
72. Seidensticker, M. J.; Behrens, J. Biochemical interactions in the wnt pathway. Biochim. Biophys. Acta, 2000, 1495, 168-182.
73. Müller, W. A.; Teo, R.; Möhrlen, F. Patterning a multi-headed mutant in Hydractinia: enhancement of head formation and its phenotypic normalization. Int. J. Dev. Biol., 2004, 48, 9-15.
74. Plickert, G.; Jacoby, V.; Frank, U.; Müller, W. A.; Mokady, O. Wnt signaling in hydroid development: formation of the primary body axis in embryogenesis and its subsequent patterning. Dev. Biol., 2006, 298, 368-378.
75. Teo, R.; Möhrlen, F.; Plickert, G.; Müller, W. A.; Frank, U. An evolutionary conserved role of Wnt signaling in stem cell fate decision. Dev. Biol., 2006, 289, 91-99.
76. Müller, W.; Frank, U.; Teo, R.; Mokady, O.; Guette, C.; Plickert, G. Wnt signaling in hydroid development: ectopic heads and giant buds induced by GSK-3beta inhibitors. Int. J. Dev. Biol., 2007, 51, 211-220.
77. Rentzsch, F.; Hobmayer, B.; Holstein, T. W. Glycogen synthase kinase 3 has a proapoptotic function in Hydra gametogenesis. Dev. Biol., 2005, 278, 1-12.
78. Schneider, S. Q.; Bowerman, B. beta-Catenin asymmetries after all animal/vegetal-oriented cell divisions in Platynereis dumerilii embryos mediate binary cell-fate specification. Dev. Cell, 2007, 13, 73-86.
79. Acevedo, N.; Wang, X.; Dunn, R. L.; Smith, G. D. Glycogen synthase kinase-3 regulation of chromatin segregation and cytokinesis in mouse preimplantation embryos. Mol. Reprod. Dev., 2007, 74, 178-188.
80. Sato, N.; Meijer, L.; Skaltsounis, L.; Greengard, P.; Brivanlou, A. H. Maintenance of pluripotency in human and mouse embryonic stem cells through activation of Wnt signaling by a pharmacological GSK-3-specific inhibitor. Nat. Med., 2004, 10, 55-63.
81. Lyssiotis, C. A.; Foreman, R. K.; Staerk, J.; Garcia, M.; Mathur, D.; Markoulaki, S.; Hanna, J.; Lairson, L. L.; Charette, B. D.; Bouchez, L. C.; Bollong, M.; Kunick, C.; Brinker, A.; Cho, C. Y.; Schultz, P. G.; Jaenisch, R. Reprogramming of murine fibroblasts to induced pluripotent stem cells with chemical complementation of Klf4. Proc. Natl. Acad. Sci. USA, 2009, 106, 8912-8917.
82. Hanna, J.; Markoulaki, S.; Mitalipova, M.; Cheng, A. W.; Cassady, J. P.; Staerk, J.; Carey, B. W.; Lengner, C. J.; Foreman, R.; Love, J.; Gao, Q.; Kim, J.; Jaenisch, R. Metastable pluripotent states in NOD-mouse-derived ESCs. Cell Stem Cell, 2009, 4, 513-524.
83. Doerig, C.; Meijer, L.; Mottram, J. C. Protein kinases as drug targets in parasitic protozoa. Trends Parasitol., 2002, 18, 366-371.
84. Bhattacharjee, A. K.; Geyer, J. A.; Woodard, C. L.; Kathcart, A. K.; Nichols, D. A.; Prigge, S. T.; Li, Z.; Mott, B. T.; Waters, N. C. A three-dimensional in silico pharmacophore model for inhibition of Plasmodium falciparum cyclin-dependent kinases and discovery of different classes of novel Pfmrk specific inhibitors. J. Med. Chem., 2004, 47, 5418-5426.
85. Grant, K. M.; Dunion, M. H.; Yardley, V.; Skaltsounis, A. L.; Marko, D.; Eisenbrand, G.; Croft, S. L.; Meijer, L.; Mottram, J. C. Inhibitors of Leishmania mexicana CRK3 cyclin-dependent kinase: chemical library screen and antileishmanial activity. Antimicrob. Agents Chemother., 2004, 48, 3033-3042.
86. Reichwald, C.; Shimony, O.; Sacerdoti-Sierra, N.; Jaffe, C. L.; Kunick, C. A new Heck reaction modification using ketone Mannich bases as enone precursors: parallel synthesis of antileishmanial chalcones. Bioorg. Med. Chem. Lett., 2008, 18, 1985-1989.
87. Reichwald, C.; Shimony, O.; Dunkel, U.; Sacerdoti-Sierra, N.; Jaffe, C. L.; Kunick, C. 2-(3-Aryl-3-oxopropen-1-yl)-9-tert-butylpaullones: a new antileishmanial chemotype. J. Med. Chem., 2008, 51, 659-665.
88. Ojo, K. K.; Gillespie, J. R.; Riechers, A. J.; Napuli, A. J.; Verlinde, C. L.; Buckner, F. S.; Gelb, M. H.; Domostoj, M. M.; Wells, S. J.; Scheer, A.; Wells, T. N.; Van Voorhis, W. C. Glycogen synthase kinase 3 is a potential drug target for African trypanosomiasis therapy. Antimicrob. Agents Chemother., 2008, 52, 3710-3717.
89. Droucheau, E.; Primot, A.; Thomas, V.; Mattei, D.; Knockaert, M.; Richardson, C.; Sallicandro, P.; Alano, P.; Jafarshad, A.; Baratte, B.; Kunick, C.; Parzy, D.; Pearl, L.; Doerig, C.; Meijer, L. Plasmodium falciparum glycogen synthase kinase-3: molecular model, expression, intracellular localisation and selective inhibitors. Biochim. Biophys. Acta, 2004, 1697, 181-196.
90. Droucheau, E.; Primot, A.; Thomas, V.; Mattei, D.; Knockaert, M.; Richardson, C.; Sallicandro, P.; Alano, P.; Jafarshad, A.; Baratte, B.; Kunick, C.; Parzy, D.; Pearl, L.; Doerig, C.; Meijer, L. Plasmodium falciparum glycogen synthase kinase-3: molecular model, ex pression, intracellular localisation and selective inhibitors (Erratum). Biochim. Biophys. Acta, 2004, 1700, 139-140.
91. Knockaert, M.; Wieking, K.; Schmitt, S.; Leost, M.; Grant, K. M.; Mottram, J. C.; Kunick, C.; Meijer, L. Intracellular targets of paullones: Identification following affinity purification on immobilized inhibitor. J. Biol. Chem., 2002, 277, 25493-25501.
92. Becker, A.; Kohfeld, S.; Lader, A.; Preu, L.; Pies, T.; Wieking, K.; Ferandin, Y.; Knockaert, M.; Meijer, L.; Kunick, C. Development of 5-benzylpaullones and paullone-9-carboxylic acid alkyl esters as selective inhibitors of mitochondrial malate dehydrogenase (mMDH). Eur. J. Med. Chem., 2010, 45, 335-342.
93. Trapp, J.; Jochum, A.; Meier, R.; Saunders, L.; Marshall, B.; Kunick, C.; Verdin, E.; Goekjian, P.; Sippl, W.; Jung, M. Adenosine mimetics as inhibitors of NAD+-dependent histone deacetylases, from kinase to sirtuin inhibition. J. Med. Chem., 2006, 49, 7307-7316.
94. Dobrov, A.; Arion, V. B.; Kandler, N.; Ginzinger, W.; Jakupec, M. A.; Rufińska, A.; Graf von Keyserlingk, N.; Galanski, M.; Kowol, C.; Keppler, B. K. The first metal-based paullone derivative with high antiproliferative activity. Inorg. Chem., 2006, 45, 1945-1950.
95. Ginzinger, W.; Arion, V. B.; Giester, G.; Galanski, M.; Keppler, B. K. Synthesis and structural peculiarities of gallium complexes with novel paullone derivatives. Cent. Eur. J. Chem., 2008, 6, 340-346.
96. Schmid, W. F.; Zorbas-Seifried, S.; John, R. O.; Arion, V. B.; Jakupec, M. A.; Roller, A.; Galanski, M.; Chiorescu, I.; Zorbas, H.; Keppler, B. K. The first ruthenium-based paullones: syntheses, Xray diffraction structures, and spectroscopic and antiproliferative properties. Inorg. Chem., 2007, 46, 3645-3656.
97. Schmid, W. F.; John, R. O.; Mühlgassner, G.; Heffeter, P.; Jakupec, M. A.; Galanski, M.; Berger, W.; Arion, V. B.; Keppler, B. K. Metal-based paullones as putative CDK inhibitors for antitumor chemotherapy. J. Med. Chem., 2007, 50, 6343-6355.
98. Anand, R.; Maksimoska, J.; Pagano, N.; Wong, E. Y.; Gimotty, P. A.; Diamond, S. L.; Meggers, E.; Marmorstein, R. Toward the development of a potent and selective organoruthenium mammalian sterile 20 kinase inhibitor. J. Med. Chem., 2009, 52, 1602-1611.
99. Brault, L.; Migianu, E.; Néguesque, A.; Battaglia, E.; Bagrel, D.; Kirsch, G. New thiophene analogues of kenpaullone: synthesis and biological evaluation in breast cancer cells. Eur. J. Med. Chem., 2005, 40, 757-763.
100. Link, A.; Kunick, C. d-Fused [1]benzazepines with selective antitumor activity: synthesis and structure-activity relationships. J. Med. Chem., 1998, 41, 1299-1305.
101. Link, A.; Zaharevitz, D. W.; Kunick, C. Antitumor pyrido[3,2-d][1]benzazepines: Synthesis and activity of thiophene analogs. Pharmazie, 1999, 54, 163-166.
102. Prühs, C.; Kunick, C. Darpones and water-soluble aminobutoxylated darpone derivatives are distinguished by matrix COMPARE analysis. Bioorg. Med. Chem. Lett., 2007, 17, 1850-1854.
103. Schultz, C.; Link, A.; Kunick, C. Aryl rings are part of the darpone pharmacophore. Arch. Pharm. Pharm. Med. Chem., 2001, 334, 163-166.
104. Kohfeld, S.; Jones, P. G.; Totzke, F.; Schächtele, C.; Kubbutat, M. H. G.; Kunick, C. 1-Aryl-4,6-dihydropyrazolo[4,3-d][1] benzazepin-5(1H)-ones: a new class of antiproliferative agents with selectivity for human leukemia and breast cancer cell lines. Eur. J. Med. Chem., 2007, 42, 1317-1324.
105. Egert-Schmidt, A.; Dreher, J.; Dunkel, U.; Kohfeld, S.; Preu, L.; Weber, H.; Ehlert, J.; Mutschler, B.; Totzke, F.; Schächtele, C.; Kubbutat, M.; Baumann, K.; Kunick, C. Identification of 2-anilino-9-methoxy-5,7-dihydro-6H-pyrimido[5,4-d][1]benzazepin-6-ones as dual PLK1/VEGF-R2 kinase inhibitor chemotypes by structurebased lead generation. J. Med. Chem., 2010, 53, 2433-2442.